Date of Award
7-1-2021
Document Type
Open Access Thesis
Degree Name
Master of Medical Science (MMSc)
First Advisor
Emmanuelle Schindler, MD, PhD
Abstract
Migraine is a paroxysmal pain disorder managed with abortive therapy during a pain attack, prophylactic therapy to prevent attacks, and often a combination of both. Calcitonin gene-related peptide (CGRP) and its receptor have a role in the provocation of migraines, and therefore have been targeted in the development of both preventive and abortive therapies. However, there is limited research investigating concomitant use of the therapies. This study will examine the safety and efficacy of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the CGRP ligand or receptor for the preventive treatment of migraine. A biphasic trial with a randomized, double-blind, placebo-controlled Primary Phase and an open label Secondary Phase will assess efficacy as measured by freedom from pain at 2 hours. The results of this study have the potential to improve and expand the management approaches used for migraine patients.
Recommended Citation
Leggio, Carina, "Efficacy of Rimegepant Plus Calcitonin Gene-Related Peptide Monoclonal Antibody for Migraine" (2021). Yale School of Medicine Physician Associate Program Theses. 90.
https://elischolar.library.yale.edu/ysmpa_theses/90
